Travere Therapeutics Inc
Sector: Manufacturing
Industry: Pharmaceutical Products
14.92
0.35
(2.4%)
Volume:
1,101,182
52 week range:
5.12 - 25.29
Market Cap:
1.324B
Company Description:
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.